AP NEWS
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Hologic Launches New Scalable Options for Panther System in the United States and Europe

February 5, 2020 GMT

MARLBOROUGH, Mass.--(BUSINESS WIRE)--Feb 5, 2020--

New product offerings within the Panther Scalable Solutions (PSS) portfolio are now commercially available in the United States and Europe, Hologic (Nasdaq: HOLX) announced today. These new optional configurations, which represent Hologic’s next generation of molecular diagnostics innovation, will allow laboratories to scale their instrumentation to meet testing demands in both their current workflow and their future growth plans.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200205005211/en/

“Our laboratory partners seek continuing efficiency and consolidation, and we are observing that trend in real time, with more Panther instruments in the field running multiple assays than ever before,” said Kevin Thornal, president, Diagnostic Solutions Division at Hologic. “In the tenth year since launching the Panther system, we are excited to add expanded capabilities to our market-leading molecular diagnostic platform.”

The Panther system, launched in Europe in 2010, offers random access and full automation for molecular testing. It provides a broad assay menu that includes tests for women’s health, sexually transmitted infections (STIs), respiratory health, and viral load, as well as Open Access functionality for laboratory developed tests (LDTs). This broad menu enables labs to consolidate molecular testing onto a single platform.

Within Panther Scalable Solutions, the Panther system functions as the foundation for optional add-ons. These add-ons include Panther Fusion, which launched in 2016 and provides additional IVD menu and the Open Access ™ functionality, the now available Panther Plus and Panther Link, as well as the upcoming Panther Trax.

Taken together, these configurable options address the needs of today’s laboratories, allowing them to increase operational capacity and testing volumes at their own pace, while building on the flexibility and streamlined user experience they require. Panther Scalable Solutions allows laboratories to choose custom configurations that best suit their needs and testing volumes as they evolve over time. These new options expand upon the proven performance and reliability of the Panther system.

The new optional configurations include:

In addition, Hologic is developing Panther Trax, which will offer the ultimate in lab automation by physically and electronically linking multiple Panther instruments together into a single, powerful workcell that allows labs to increase testing volumes without increasing staff. Panther Trax is expected to be available in the United States and Europe later in 2020.

For more information about the Panther system, visit https://www.hologic.com/hologic-products/diagnostic-solutions/instrumentation.

About the Panther System

The Panther system for molecular diagnostics is a best-in-class fully automated, sample-to-result platform with adaptable workflow options and consolidated testing menu. It combines women’s health, STI and viral load testing, which can all be done simultaneously. The Panther Fusion system provides an expanded in-vitro diagnostics (IVD) menu, as well as Open Access functionality to run laboratory developed tests. Hologic’s Panther and Panther Fusion systems now offer 16 FDA-cleared assays and 20 CE-marked assays that detect more than 20 pathogens. This high-throughput molecular diagnostic platform combines comprehensive sexual health, cervical health, viral load, respiratory testing and open channel functionality on a fully automated system.

About Hologic

Hologic, Inc. is an innovative medical technology company primarily focused on improving women’s health and well-being through early detection and treatment. For more information on Hologic, visit www.hologic.com.

Hologic Forward-Looking Statements

This press release may contain forward-looking information that involves risks and uncertainties, including statements about the use of Hologic’s diagnostic products. There can be no assurance these products will achieve the benefits described herein or that such benefits will be replicated in any particular manner with respect to an individual patient. The actual effect of the use of the products can only be determined on a case-by-case basis depending on the particular circumstances and patient in question. In addition, there can be no assurance that these products will be commercially successful or achieve any expected level of sales. Hologic expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any such statements presented herein to reflect any change in expectations or any change in events, conditions or circumstances on which any such statements are based.

Hologic, Aptima, Panther, Panther Fusion and The Science of Sure are registered trademarks of Hologic, Inc. in the United States and/or other countries.

SOURCE: Hologic, Inc.

View source version on businesswire.com:https://www.businesswire.com/news/home/20200205005211/en/

CONTACT: Investor Contact:

Michael Watts

+1 858.410.8588

michael.watts@hologic.comMedia Contact:

Jane Mazur

+1 508.263.8764 (direct)

+1 585.355.5978 (mobile)

jane.mazur@hologic.com

KEYWORD: MASSACHUSETTS EUROPE UNITED STATES NORTH AMERICA

INDUSTRY KEYWORD: BIOTECHNOLOGY TECHNOLOGY OTHER HEALTH HEALTH RADIOLOGY ONCOLOGY OTHER TECHNOLOGY MEDICAL DEVICES INFECTIOUS DISEASES SOFTWARE HARDWARE

SOURCE: Hologic, Inc.

Copyright Business Wire 2020.

PUB: 02/05/2020 08:08 AM/DISC: 02/05/2020 08:08 AM

http://www.businesswire.com/news/home/20200205005211/en